Luxturna (voretigene neparvovec)

pCPA File Number: 21334

Negotiation Status:

Concluded with an LOI

Indication(s):

Vision loss, inherited retinal dystrophy

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CADTH Project Number:

SG0643

pCPA Engagement Letter Issued:

2021-11-25

Negotiation Process Concluded:

2022-09-16